CLINICAL STUDY

Effect of long-term L-thyroxine treatment on bone mineral density in young adults with congenital hypothyroidism

Mariacarolina Salerno, Teresa Lettieri, Antonella Esposito-del Puente1, Valentina Esposito, Donatella Capalbo, Assunta Carpinelli2, Stefania Padula3 and Antonio del Puente2

Department of Pediatrics, University Federico II, 1 Department of Pediatrics, S.Maria della Pietà Hospital, and 2 Rheumatology Unit, University Federico II, Naples, Italy

(Correspondence should be addressed to M Salerno, Department of Pediatrics, University Federico II, via S. Pansini, 580131 Napoli, Italy; Email: salerno@unina.it)

Abstract

Objective: To evaluate whether long-term L-thyroxine therapy in young adults with congenital hypothyroidism may affect bone mineral density (BMD).

Design: Thirty-seven subjects with congenital hypothyroidism, detected by neonatal screening and longitudinally followed from the time of diagnosis and treatment (26±4 days) up to the age of 17.8±1.0 years, were studied.

Methods: Spinal (L2–L4) BMD, measured by dual-energy X-ray densitometry, and bone quality, measured as amplitude-dependent speed of sound (Ad-SoS) by quantitative ultrasound, were evaluated.

Results: Z-score mean values (±S.D.) of BMD (−0.3±0.7) and Ad-SoS (−0.7±1.1) were slightly below the average but within the normal range. Ad-SoS resulted in a z-score below −1 in 38% of patients as compared with BMD which resulted in a z-score below −1 in only 13.5% of subject. No significant differences were observed between males (BMD, −0.3±0.7; Ad-SoS, −0.9±1.0) and females (BMD, −0.3±0.7; Ad-SoS, −0.5±1.2) or when dividing patients on the basis of aetiological defects; ectopic gland (BMD, −0.3±0.6; Ad-SoS, −0.8±0.9), athyreosis (BMD, −0.3±0.9; Ad-SoS, −0.8±1.0) and eutopic gland (BMD, −0.3±0.8; Ad-SoS, −0.4±1.3). No significant relationships were observed between BMD or Ad-SoS z-score and hormonal status or L-thyroxine dosages at the time of the study or during the pubertal period.

Conclusions: The careful monitoring of serum thyroid-stimulating hormone and adjustment of L-thyroxine dosage avoided the significant deleterious effects of prolonged L-thyroxine replacement therapy on bone tissue in adolescents and young adults with congenital hypothyroidism treated from the neonatal period.

Introduction

Osteoporosis is one of the major health problems in adults (1); however, this condition has recently become a pediatric concern, too. In fact, the most important factor in the prevention of osteoporosis is the attainment of an optimal peak bone mass, which is mainly reached during late adolescence or early adulthood (2). In healthy subjects, bone mass increases through childhood, with maximal bone mass accrual occurring in early to mid puberty and continuing, at a lower rate, in late puberty (2–4); thus osteoporosis prevention should begin at this age. The attainment of peak bone mass is the result of interaction of several factors such as genetic, ethnic, hormonal and nutritional factors, lifestyle and physical activity (5, 6). Any factors adversely impacting on bone acquisition during childhood and adolescence can potentially have long-lasting detrimental effects on bone tissue, predisposing it to osteoporosis. Therefore, young people affected by chronic pathologies, which are potentially harmful for the bone, should be screened for bone disturbance. Thyroid disease is one of the most common endocrine disorders in both childhood and adulthood. In adults with thyroid cancer, goiters or thyroid nodules, treatment with high doses of L-thyroxine (L-T4), aimed at suppressing serum thyroid-stimulating hormone (TSH) levels, leads to prolonged subclinical hyperthyroidism, which has been associated with reduced bone mass and premature development of osteoporosis (7). Thyroid hormones directly affect bone cells stimulating osteoclastic and osteoblastic activity, with a predominance of bone resorption during hyperthyroidism, resulting in a decreased bone mass (8, 9). A significant reduction of peripheral bone mineral density (BMD) has been found in children and adolescents receiving L-T4 overtreatment for goiter, Hashimoto’s thyroiditis or thyroid cancer (10), however
other studies indicated that long-term L-T4 treatment does not seem to affect bone mineral metabolism and BMD in patients with thyroid diseases (11–14). Congenital hypothyroidism (CH) is one of the most common thyroid diseases in children; early detection by neonatal screening has significantly improved mental and auxological outcomes. A few data on bone mineral metabolism in children with CH are reassuring (11, 13); however, there are no data on young adults with CH detected by neonatal screening. The aim of the present study was to evaluate whether long-term L-T4-replacement therapy in young adults with CH, detected by neonatal screening and treated since the first weeks of life, may affect BMD.

Patients and methods

Patients

A total of 37 Caucasian patients (25 females, 12 males) aged 17.8±1.0 years (range 16.0–19.6 years) with CH participated in the study. All patients had been detected by neonatal screening and followed longitudinally, from the time of diagnosis to the time of the study. Patients with other chronic diseases were excluded from the study. The diagnosis was confirmed by serum thyroid function tests. L-T4 replacement therapy started immediately after the first evaluation, at a mean initial dose of 6.6±0.9 μg/kg per day. Replacement therapy was modified during follow-up according to clinical and hormonal evaluation in order to maintain serum TSH levels in the normal range and serum free thyroxine in the upper normal range. The aetiological diagnosis of CH was made on the basis of technetium-99m (99m Tc)-pertechnetate or iodine-123 thyroid scans at the time of diagnosis or at the age of 3 years, after the withdrawal of L-T4 therapy for 6 weeks. Cases were classified into three groups: athyreosis (n=10), ectopic gland (n=19) and eutopic gland (n=8).

At study entry all patients underwent height and weight measurement; the degree of adiposity was expressed as body mass index (BMI; weight/height²). All subjects had completed their pubertal development (15), females had regular menstrual cycles (every 25–35 days) and all patients had already reached their adult height (defined as a growth of less than 1.0 cm/year during the preceding year). Serum calcium, phosphorus, alkaline phosphatase, parathyroid hormone (PTH), TSH and thyroid hormones were determined in the morning after a 12-h fast. All subjects had normal liver and kidney function and did not take drugs known to affect skeletal or mineral metabolism. None of them had a history of hereditary bone disease.

The total daily calcium intake was calculated by a semiquantitative food frequency questionnaire, specifically compiled to investigate the calcium consumption (16). All subjects had normal physical activity. Five patients were mild smokers (less than 10 cigarettes per day) and three were moderate drinkers (beer or wine occasionally). In order to evaluate the influence of thyroid hormone status on bone mass accrual during puberty, mean values were calculated from all serum TSH and serum free thyroxine evaluations carried out from the onset of puberty to the time of the study; the mean L-T4 dose taken in the same period of time was also calculated.

Informed consent to participate into the study was obtained from the patients’ parents when the chronological age was lower than 18 years, and directly from each older subject.

Bone densitometry

The BMD was measured by dual energy X-ray absorptiometry (DXA), using an Hologic QDR 1000 densitometer (Hologic, Waltham, MA, USA) at the lumbar spine (L2–L4). Daily phantom scanning during a 1-year period yielded a coefficient of variation of 0.56%. Measurements were always performed by the same operator. Individual BMD values were expressed as g/cm² and as BMD z-score, calculated on the basis of the normal reference values for age and sex provided by the DXA system manufacturer; their data in fact did not differ significantly from those obtained on a local sample in a study performed when the machine was set up (17). In order to obtain more complete information on bone tissue, young adults with CH were also investigated by quantitative ultrasound (QUS) measurements using a DBM Sonic 1200R bone profiler (Igea S.r.l., Carpi, MO, Italy). The sound frequency employed was 1.25 MHz, and the amplitude-dependent speed of sound (Ad-SoS) was determined. QUS was performed on the second to the fifth proximal phalanges of the non-dominant hand and the mean value per person was calculated. Measurements were always performed by the same operator and the coefficient of variation was 0.73%, determined by repeated measurements in a subgroup of 12 subjects (three measurements per person on three different days). Ad-SoS results were expressed as z-scores calculated on the basis of the normal values for age and sex obtained in a large Italian population sample (18). Among adults both BMD and Ad-SoS z-score can be considered within the normal range when above −1 SDS, while different values identify osteopenic or osteoporotic patients (19). At present no consensus exists in pediatric patients, but it seems reasonable to consider the same consecutive cut-off (−1 SDS) at least for normality definition, especially as we are dealing with a study population of young adults.

Statistical analysis

To give greater power to the statistical analysis, we used as a control group the large reference population.
samples mentioned previously (18). The sample size was calculated assuming the conventional value of \( \alpha = 0.05 \) and a value of \( \beta = 0.2 \). The expected difference for the variables of interest (BMD and Ad-SoS) was 10%. Considering an \( \text{s.D.} \) value of up to 10% for such variables, the number of cases needed was estimated to be at least 16.

Data are reported as means \( \pm \text{s.D.} \). The statistical analysis was performed using the Student’s \( t \)-test for unpaired data and the Mann–Whitney rank-sum test as appropriate. Regression coefficients were computed by multiple regression analysis. Statistical significance was indicated by \( P < 0.05 \).

**Results**

Clinical, biochemical and hormonal findings as well as BMD and QUS results of CH patients are reported in Table 1. Z-score mean values for BMD (\(-0.3 \pm 0.7\) SDS) and Ad-SoS (\(-0.7 \pm 1.1\) SDS) resulted within the normal range, even though the analysis of 95% confidence intervals (CI) indicates that z-score mean values are slightly but significantly different (95% CI not inclusive of zero) from the reference mean value for both BMD (CI, \(-0.53\) to \(-0.06\)) and Ad-SoS (CI, \(-1.1\) to \(-0.35\)). In the majority of patients (86.5%) BMD resulted in a z-score of between +2 and -1; in only five subjects (13.5%) and was BMD below a z-score of -1. Ad-SoS showed a z-score between +2 and -1 in 62%, but 14 out 37 patients (38%) showed z-score values below -1.

No significant differences were observed between males (BMD, \(-0.3 \pm 0.7\) SDS; Ad-SoS, \(0.9 \pm 1.0\) SDS) and females (BMD, \(-0.3 \pm 0.7\) SDS; Ad-SoS, \(-0.5 \pm 1.2\) SDS) as shown in Table 1, or dividing patients on the basis of aetiological defect; ectopic gland (BMD, \(-0.3 \pm 0.6\) SDS; Ad-SoS, \(-0.8 \pm 0.9\) SDS), athyreosis (BMD, \(-0.3 \pm 0.9\) SDS; Ad-SoS, \(-0.8 \pm 1.0\) SDS) and eutropic gland (BMD, \(-0.3 \pm 0.8\) SDS; Ad-SoS, \(-0.4 \pm 1.3\) SDS) (Fig. 1).

Daily calcium intake was below the recommended intake of 1300 mg/day (5%) in the majority of patients. Results from the food frequency questionnaire showed that the mean calcium consumption in our patients was \(829 \pm 354\) mg/day (range \(317–2037\) mg/day). In 18 subjects (48.6%) with a calcium intake of below 800 mg/day (mean \(\pm\) s.D., \(571 \pm 137\) mg/day), BMD z-score (\(-0.4 \pm 0.8\) SDS) and Ad-SoS z-score (\(-0.8 \pm 1.1\) SDS) were not different from patients with higher (1073 \pm 323 mg/day) calcium consumption (BMD z-score, \(-0.2 \pm 0.6\) SDS; Ad-SoS z-score, \(-0.7 \pm 1.2\) SDS).

Four females, with familial delay of puberty, who experienced menarche at a mean age of 15.1 \pm 0.9 years, showed a significant reduction in BMD z-score (\(-1.3 \pm 0.7\) SDS) as compared with females who had menarche at a mean age of 12.1 \pm 0.9 years (BMD z-score, \(-0.1 \pm 0.5\) SDS; \(P < 0.0007\)). Ad-SoS z-score was also lower in females with delayed menarche (\(-1.5 \pm 1.1\) versus \(0.8 \pm \) 1.0 SDS); however, the difference was not statistically significant. Moreover, no significant differences were observed between the two groups with regard to serum TSH, serum thyroid hormones or l-T4 replacement therapy either at the time of the study or during the pubertal period; however, a trend towards repeatedly higher serum TSH values was observed in girls with delayed puberty, as showed in Table 2. Using multiple regression analysis, no significant relationships were observed between z-scores of BMD or Ad-SOS and hormonal status or l-T4 dosages at the time of the study or during the pubertal period, controlling for confounding variables.

| Table 1 Main clinical, biochemical and bone mineral data (means \(\pm\) s.D.) of subjects with CH. Pubertal values are mean values from the onset of puberty to the time of the study. |
|---|---|---|
| **Age (years)** | All (n = 37) | Males (n = 12) | Females (n = 25) |
| | 17.8 \(\pm\) 1.0 | 17.6 \(\pm\) 0.8 | 17.9 \(\pm\) 1.1 |
| **Height (cm)** | 166.1 \(\pm\) 8.5 | 174.2 \(\pm\) 8.8 | 162.2 \(\pm\) 5.0 |
| **Target height (cm)** | 160.6 \(\pm\) 7.3 | 166.5 \(\pm\) 7.4 | 157.7 \(\pm\) 5.4 |
| **Body mass index (kg/m²)** | 23.0 \(\pm\) 3.3 | 23.5 \(\pm\) 3.5 | 23.0 \(\pm\) 3.0 |
| **Serum TSH (mU/l)** | 3.0 \(\pm\) 3.2 | 3.4 \(\pm\) 2.6 | 2.9 \(\pm\) 3.0 |
| **Serum FT4 (pmol/l)** | 16.8 \(\pm\) 2.7 | 16.7 \(\pm\) 1.9 | 17.0 \(\pm\) 3.0 |
| **L-T4 (\(\mu\)g/kg/day)** | 21.0 \(\pm\) 4.0 | 2.0 \(\pm\) 0.4 | 2.2 \(\pm\) 0.4 |
| **Serum calcium (mM/l)** | 2.5 \(\pm\) 0.1 | 2.5 \(\pm\) 0.1 | 2.5 \(\pm\) 0.1 |
| **Serum phosphorous (mM/l)** | 1.4 \(\pm\) 0.2 | 1.3 \(\pm\) 0.2 | 1.4 \(\pm\) 0.3 |
| **Total alkaline phosphatase (U/l)** | 181 \(\pm\) 73 | 229 \(\pm\) 105 | 160 \(\pm\) 44 |
| **Serum PTH (pmol/l)** | 2.8 \(\pm\) 0.9 | 3.2 \(\pm\) 1.0 | 2.8 \(\pm\) 0.9 |
| **Calcium intake (mg/day)** | 829 \(\pm\) 354 | 856 \(\pm\) 446 | 816 \(\pm\) 311 |
| **Pubertal mean serum TSH (mU/l)** | 4.3 \(\pm\) 2.8 | 3.9 \(\pm\) 1.3 | 4.4 \(\pm\) 3.3 |
| **Pubertal mean serum FT4 (mU/l)** | 19.3 \(\pm\) 2.5 | 18.9 \(\pm\) 1.7 | 19.6 \(\pm\) 2.9 |
| **Pubertal mean l-T4 (\(\mu\)g/kg/day)** | 2.5 \(\pm\) 1.1 | 2.2 \(\pm\) 0.7 | 2.6 \(\pm\) 1.3 |
| **BMD z-score** | \(-0.3 \pm 0.7\) | \(-0.3 \pm 0.7\) | \(-0.3 \pm 0.7\) |
| **Ad-SoS z-score** | \(-0.7 \pm 1.1\) | \(-0.6 \pm 1.2\) | \(-0.5 \pm 1.2\) |
Table 2 Hormonal and bone mineral data (means±s.d.) in females with CH divided on the basis of pubertal development. Pubertal values are mean values from the onset of puberty to the time of the study.

<table>
<thead>
<tr>
<th></th>
<th>Normal puberty (n = 21)</th>
<th>Delayed puberty (n = 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum TSH (mU/l)</td>
<td>2.3±2.9</td>
<td>5.7±4.3</td>
</tr>
<tr>
<td>Serum FT4 (pM/l)</td>
<td>13.5±2.1</td>
<td>11.4±3.1</td>
</tr>
<tr>
<td>L-T4 (μg/kg/day)</td>
<td>2.1±0.4</td>
<td>2.2±0.2</td>
</tr>
<tr>
<td>Pubertal mean serum TSH (mU/l)</td>
<td>4.1±3.2</td>
<td>5.7±3.9</td>
</tr>
<tr>
<td>Pubertal mean serum FT4 (pM/l)</td>
<td>15.1±2.4</td>
<td>15.5±1.5</td>
</tr>
<tr>
<td>Pubertal mean L-T4 (μg/kg/day)</td>
<td>2.6±1.3</td>
<td>2.5±0.9</td>
</tr>
<tr>
<td>BMD z-score</td>
<td>0.1±0.5</td>
<td>1.3±0.7*</td>
</tr>
<tr>
<td>Ad-SoS z-score</td>
<td>0.8±1.0</td>
<td>1.5±1.1</td>
</tr>
</tbody>
</table>

* P < 0.0007 versus females with normal puberty.
bone mineral status while an increment in bone mass and bone density is observed with dietary calcium supplement (29, 30). In this study we did not observe a difference in both BMD and QUS between patients with low or normal calcium intake. However this was not among the aims of the study. Of different methods of bone-mass evaluation currently in use, DXA is considered the gold standard for BMD measurement. However, ultrasound instruments using attenuation and/or velocity propagation determinations, not based on radioactive sources or ionizing radiation, have been developed for the screening of subjects at high risk of osteoporosis (31). QUS is a new and non-invasive method of evaluating bone tissue, and it is more sensitive to structural bone changes than the traditional methods because ultrasound velocity depends on bone density, architecture and elasticity (18). In our study, as in others, QUS and DXA gave similar results in the evaluation of patients with chronic pathologies potentially affecting bone metabolism (32).

In conclusion our results indicate that the careful monitoring of serum TSH and adjustment of L-T4 dosage avoided significant deleterious effects of prolonged l-T4-replacement therapy on bone tissue in patients with CH. The finding of reduced bone density in a low percentage of patients, mainly detected by QUS, suggests that, during history-taking in an adult patient in whom skeletal health is being reviewed, l-T4 replacement in childhood may prove to be a potential adverse factor.

Acknowledgements

We thank Stefania Leopaldi for her technical assistance.

References

27 Jernelov A. Thyroid hormone and bone. Hormone Research 1998 50 315–324.
28 Jernelov A. Thyroid hormone and bone. Hormone Research 1998 50 315–324.
29 Jernelov A. Thyroid hormone and bone. Hormone Research 1998 50 315–324.
30 Jernelov A. Thyroid hormone and bone. Hormone Research 1998 50 315–324.
31 Jernelov A. Thyroid hormone and bone. Hormone Research 1998 50 315–324.
32 Jernelov A. Thyroid hormone and bone. Hormone Research 1998 50 315–324.
33 Jernelov A. Thyroid hormone and bone. Hormone Research 1998 50 315–324.
34 Jernelov A. Thyroid hormone and bone. Hormone Research 1998 50 315–324.
35 Jernelov A. Thyroid hormone and bone. Hormone Research 1998 50 315–324.
36 Jernelov A. Thyroid hormone and bone. Hormone Research 1998 50 315–324.


Received 26 May 2004
Accepted 13 September 2004